Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,674.20 | 49.30 | -0.57% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,516.76 | 13.72 | -0.06% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,252.46 | 150.77 | -0.39% |
| NZX 50 Index | 12,520.09 | 48.96 | -0.39% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,461.30 | 44.20 | -0.52% |
| SSE Composite Index | 3,365.07 | 5.17 | 0.15% |